[
  {
    "company_name": "Baxter International Inc.",
    "symbol": "BAX",
    "overall_sentiment": "neutral",
    "financials": {
      "revenue_growth": "+2% reported, +3% constant currency",
      "eps_change": "Q2 EPS below expectations, Q1 margins above expectations",
      "rd_investment_change": "Increasing R&D dollar value in 2024 and 2025, though not as a percentage of sales",
      "outlook_summary": "Full year global sales growth guidance increased for MPT; Q2 and full year outlook provided."
    },
    "executives": [
      {
        "name": "José Almeida",
        "role": "Chairman and Chief Executive Officer",
        "sentiment": "positive"
      },
      {
        "name": "Joel Grade",
        "role": "Executive Vice President and Chief Financial Officer",
        "sentiment": "positive"
      },
      {
        "name": "Clare Trachtman",
        "role": "N/A",
        "sentiment": "neutral"
      }
    ],
    "technologies": [
      {
        "technology_name": "Healthcare tech",
        "technology_sentiment": "negative",
        "investment_action": "unclear",
        "investment_horizon": "unclear",
        "profit_outlook": "unclear",
        "rd_investment": "unclear",
        "revenue_impact": "underperformed in Q1",
        "mentioned_by": "Vijay Kumar"
      },
      {
        "technology_name": "Novum IQ",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "ongoing",
        "profit_outlook": "unclear",
        "rd_investment": "unclear",
        "revenue_impact": "contribute incremental $25 million to infusion pump sales",
        "mentioned_by": "José Almeida"
      },
      {
        "technology_name": "Smart beds",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "ongoing",
        "profit_outlook": "unclear",
        "rd_investment": "unclear",
        "revenue_impact": "unclear",
        "mentioned_by": "José Almeida"
      },
      {
        "technology_name": "Connectivity Solutions",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "long-term",
        "profit_outlook": "high potential",
        "rd_investment": "unclear",
        "revenue_impact": "delivering bigger sales impacts as we move into '25 and 2026",
        "mentioned_by": "Joshua Jennings"
      },
      {
        "technology_name": "Connex gateway",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "ongoing",
        "profit_outlook": "unclear",
        "rd_investment": "unclear",
        "revenue_impact": "connects devices",
        "mentioned_by": "José Almeida"
      },
      {
        "technology_name": "Drug compounding",
        "technology_sentiment": "positive",
        "investment_action": "maintaining",
        "investment_horizon": "ongoing",
        "profit_outlook": "high potential",
        "rd_investment": "unclear",
        "revenue_impact": "high double-digit growth",
        "mentioned_by": "Robert Marcus"
      }
    ],
    "year": 2024,
    "quarter": 1,
    "date": "2024-05-02 08:30:00"
  },
  {
    "company_name": "Baxter International Inc.",
    "symbol": "BAX",
    "overall_sentiment": "positive",
    "financials": {
      "revenue_growth": "3% reported, 4% constant currency",
      "eps_change": "24% increase YoY for adjusted EPS",
      "rd_investment_change": "unclear",
      "outlook_summary": "Increased full year sales outlook and adjusted EPS guidance; expect full year adjusted EPS of $2.93 to $3.01"
    },
    "executives": [
      {
        "name": "Joe Almeida",
        "role": "Chairman and Chief Executive Officer",
        "sentiment": "positive"
      },
      {
        "name": "Joel Grade",
        "role": "Executive Vice President and Chief Financial Officer",
        "sentiment": "positive"
      },
      {
        "name": "Clare Trachtman",
        "role": "Senior Vice President, Chief Investor Relations Officer",
        "sentiment": "neutral"
      }
    ],
    "technologies": [
      {
        "technology_name": "Patient Support Systems",
        "technology_sentiment": "positive",
        "investment_action": "maintaining",
        "investment_horizon": "ongoing",
        "profit_outlook": "unclear",
        "rd_investment": "unclear",
        "revenue_impact": "positive",
        "mentioned_by": "Joel Grade"
      },
      {
        "technology_name": "Infusion Therapies",
        "technology_sentiment": "positive",
        "investment_action": "maintaining",
        "investment_horizon": "ongoing",
        "profit_outlook": "unclear",
        "rd_investment": "unclear",
        "revenue_impact": "positive",
        "mentioned_by": "Joel Grade"
      },
      {
        "technology_name": "Peritoneal Dialysis",
        "technology_sentiment": "positive",
        "investment_action": "maintaining",
        "investment_horizon": "ongoing",
        "profit_outlook": "unclear",
        "rd_investment": "unclear",
        "revenue_impact": "positive",
        "mentioned_by": "Joel Grade"
      },
      {
        "technology_name": "Drug Compounding",
        "technology_sentiment": "positive",
        "investment_action": "maintaining",
        "investment_horizon": "ongoing",
        "profit_outlook": "moderate potential",
        "rd_investment": "unclear",
        "revenue_impact": "+",
        "mentioned_by": "Joel Grade"
      },
      {
        "technology_name": "IV solutions",
        "technology_sentiment": "positive",
        "investment_action": "maintaining",
        "investment_horizon": "ongoing",
        "profit_outlook": "unclear",
        "rd_investment": "unclear",
        "revenue_impact": "positive",
        "mentioned_by": "Joel Grade"
      },
      {
        "technology_name": "Infusion systems",
        "technology_sentiment": "positive",
        "investment_action": "maintaining",
        "investment_horizon": "ongoing",
        "profit_outlook": "unclear",
        "rd_investment": "unclear",
        "revenue_impact": "positive",
        "mentioned_by": "Joel Grade"
      },
      {
        "technology_name": "Nutrition",
        "technology_sentiment": "positive",
        "investment_action": "maintaining",
        "investment_horizon": "ongoing",
        "profit_outlook": "unclear",
        "rd_investment": "unclear",
        "revenue_impact": "positive",
        "mentioned_by": "Joel Grade"
      },
      {
        "technology_name": "Novum platform",
        "technology_sentiment": "positive",
        "investment_action": "maintaining",
        "investment_horizon": "ongoing",
        "profit_outlook": "unclear",
        "rd_investment": "unclear",
        "revenue_impact": "positive",
        "mentioned_by": "Clare Trachtman"
      },
      {
        "technology_name": "Care and Connectivity Solutions",
        "technology_sentiment": "positive",
        "investment_action": "maintaining",
        "investment_horizon": "ongoing",
        "profit_outlook": "unclear",
        "rd_investment": "unclear",
        "revenue_impact": "positive",
        "mentioned_by": "Joel Grade"
      },
      {
        "technology_name": "FLC",
        "technology_sentiment": "positive",
        "investment_action": "maintaining",
        "investment_horizon": "ongoing",
        "profit_outlook": "unclear",
        "rd_investment": "unclear",
        "revenue_impact": "positive",
        "mentioned_by": "Clare Trachtman"
      }
    ],
    "year": 2024,
    "quarter": 2,
    "date": "2024-08-06 08:30:00"
  },
  {
    "company_name": "Baxter International Inc.",
    "symbol": "BAX",
    "overall_sentiment": "positive",
    "financials": {
      "revenue_growth": "+4%",
      "eps_change": "+14% (adjusted continuing operations)",
      "rd_investment_change": "modest growth",
      "outlook_summary": "Expects modest growth in R&D, leverage in SG&A, full business recovery from operational issues by end of Q4 2024, and stabilization of Primary Care market into 2025."
    },
    "executives": [
      {
        "name": "Joe Almeida",
        "role": "Chairman and Chief Executive Officer",
        "sentiment": "positive"
      },
      {
        "name": "Joel Grade",
        "role": "Executive Vice President and Chief Financial Officer",
        "sentiment": "positive"
      },
      {
        "name": "Clare Trachtman",
        "role": "Moderator",
        "sentiment": "neutral"
      },
      {
        "name": "David Roman",
        "role": "Analyst",
        "sentiment": "neutral"
      }
    ],
    "technologies": [
      {
        "technology_name": "Infusion Therapies",
        "technology_sentiment": "positive",
        "investment_action": "maintaining",
        "investment_horizon": "ongoing",
        "profit_outlook": "moderate potential",
        "rd_investment": "unclear",
        "revenue_impact": "+7%",
        "mentioned_by": "Joel Grade"
      },
      {
        "technology_name": "Novum IQ pump platform",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "ongoing",
        "profit_outlook": "high potential",
        "rd_investment": "unclear",
        "revenue_impact": "+7%",
        "mentioned_by": "Joel Grade"
      },
      {
        "technology_name": "Pumps and sets",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "ongoing",
        "profit_outlook": "high potential",
        "rd_investment": "unclear",
        "revenue_impact": "+7%",
        "mentioned_by": "Joe Almeida"
      },
      {
        "technology_name": "Injectables",
        "technology_sentiment": "positive",
        "investment_action": "maintaining",
        "investment_horizon": "ongoing",
        "profit_outlook": "moderate potential",
        "rd_investment": "unclear",
        "revenue_impact": "mid-single-digit growth",
        "mentioned_by": "Joe Almeida"
      }
    ],
    "year": 2024,
    "quarter": 3,
    "date": "2024-11-08 08:30:00"
  },
  {
    "company_name": "Baxter International Inc.",
    "symbol": "BAX",
    "overall_sentiment": "positive",
    "financials": {
      "revenue_growth": "+1% reported, +2% constant currency (Q4)",
      "eps_change": "-11% year-over-year (Q4 adjusted EPS)",
      "outlook_summary": "Results ahead of prior guidance on top and bottom lines. Full year 2024 sales increased 3%. Full year 2024 adjusted EPS increased 11%."
    },
    "executives": [
      {
        "name": "Brent Shafer",
        "role": "Chair and Interim Chief Executive Officer",
        "sentiment": "neutral"
      },
      {
        "name": "Joel Grade",
        "role": "Executive Vice President and Chief Financial Officer",
        "sentiment": "positive"
      },
      {
        "name": "Heather Knight",
        "role": "Chief Operating Officer",
        "sentiment": "neutral"
      },
      {
        "name": "Clare Trachtman",
        "role": "N/A",
        "sentiment": "neutral"
      }
    ],
    "technologies": [
      {
        "technology_name": "Novum pump",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "ongoing",
        "profit_outlook": "high potential",
        "rd_investment": "unclear",
        "revenue_impact": "+ significant growth",
        "mentioned_by": "Joel Grade"
      },
      {
        "technology_name": "compounding",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "ongoing",
        "profit_outlook": "moderate potential",
        "rd_investment": "unclear",
        "revenue_impact": "+ mix improvement",
        "mentioned_by": "Joel Grade"
      },
      {
        "technology_name": "AI",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "long-term",
        "profit_outlook": "high potential",
        "rd_investment": "unclear",
        "revenue_impact": "unclear",
        "mentioned_by": "unclear"
      },
      {
        "technology_name": "Cloud Computing",
        "technology_sentiment": "positive",
        "investment_action": "investing",
        "investment_horizon": "long-term",
        "profit_outlook": "high potential",
        "rd_investment": "unclear",
        "revenue_impact": "unclear",
        "mentioned_by": "unclear"
      }
    ],
    "year": 2024,
    "quarter": 4,
    "date": "2025-02-20 08:30:00"
  }
]